{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:06:10Z","timestamp":1773392770980,"version":"3.50.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,7]]},"DOI":"10.1093\/eurheartj\/ehx549","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T03:15:04Z","timestamp":1505186104000},"page":"1131-1143","source":"Crossref","is-referenced-by-count":156,"title":["2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia"],"prefix":"10.1093","volume":"39","author":[{"given":"Ulf","family":"Landmesser","sequence":"first","affiliation":[{"name":"Department of Cardiology, Charite Universit\u00e4tsmedizin Berlin, Berlin Institute of Health (BIH), German Center of Cardiovascular Research (DZHK), Hindenburgdamm 30, 12203 Berlin, Germany"}]},{"given":"M John","family":"Chapman","sequence":"additional","affiliation":[{"name":"National Institute for Health and Medical Research (INSERM), University of Pierre and Marie Curie, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}]},{"given":"Jane K","family":"Stock","sequence":"additional","affiliation":[{"name":"European Atherosclerosis Society, Gothenburg, Sweden"}]},{"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[{"name":"Paris-Diderot-Sorbonne University and Department of Neurology and Stroke Centre, Bichat Hospital, Paris, France"}]},{"given":"Jill J F","family":"Belch","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee, UK"}]},{"given":"Jan","family":"Bor\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, and Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[{"name":"Lipid Clinic, Point Medical, and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France"}]},{"given":"Brian A","family":"Ference","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Division of Translational Research and Clinical Epidemiology, Wayne State University School of Medicine, Detroit, MI, USA"}]},{"given":"Stephan","family":"Gielen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Martin-Luther-University Halle\/Wittenberg, University Hospital, Halle\/Saale, Germany"}]},{"given":"Ian","family":"Graham","sequence":"additional","affiliation":[{"name":"Trinity College, Dublin, Ireland"}]},{"given":"Diederick E","family":"Grobbee","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}]},{"given":"G Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}]},{"given":"Thomas F","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"University Heart Center, Department of Cardiology, University Hospital Zurich, and Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland"}]},{"given":"Massimo F","family":"Piepoli","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiac Department, G Da Saliceto Hospital, Piacenza, Italy"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College, London, UK"}]},{"given":"Erik S","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}]},{"given":"Olov","family":"Wiklund","sequence":"additional","affiliation":[{"name":"Sahlgrenska University Hospital, Gothenburg, Sweden"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland"}]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Ram\u00f3n y Cajal, Madrid, Spain"}]},{"given":"Fausto","family":"Pinto","sequence":"additional","affiliation":[{"name":"Cardiology Department, CCUL, CAML, Faculdade de Medicina, Universidade de Lisboa, Portugal"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hacettepe University, Ankara, Turkey"}]},{"given":"Jeroen J","family":"Bax","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands"}]},{"given":"Alberico L","family":"Catapano","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan and Multimedica IRCSS Milano, Italy"}]}],"member":"286","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"key\n\t\t\t\t20180407055351_ehx549-B1","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B5","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B6","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B7","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B10","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B11","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B12","first-page":"2245","article-title":"European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4\u2009years from the open-label OSLER-1 Extension Study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B16","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B17","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry","volume":"135","author":"P\u00e9rez de Isla","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B18","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response. A pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/clp.12.88","article-title":"The efficacy and safety of ezetimibe coadministered with statin therapy in various patients groups","volume":"8","author":"Catapano","year":"2013","journal-title":"Clin Lipidol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1358863X10373299","article-title":"Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry","volume":"15","author":"Su\u00e1rez","year":"2010","journal-title":"Vasc Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/eurheartj\/ehw548","article-title":"Prognostic assessment of stable coronary artery disease as determined by coronary computed tomography angiography: a Danish multicentre cohort study","volume":"38","author":"Nielsen","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B23","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry","volume":"30","author":"Alberts","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.291.2.210","article-title":"Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals","volume":"291","author":"Greenland","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B25","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehp272","article-title":"Incremental prognostic value of multi-slice computed tomography coronary angiography over coronary artery calcium scoring in patients with suspected coronary artery disease","volume":"30","author":"Van Werkhoven","year":"2009","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.081380","article-title":"Coronary computed tomographic angiography and risk of all-cause mortality and nonfatal myocardial infarction in subjects without chest pain syndrome from the CONFIRM Registry (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry)","volume":"126","author":"Cho","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B27","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","article-title":"Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors","volume":"200","author":"Alonso","year":"2008","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B29","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH Registry","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B31","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","article-title":"Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study)","volume":"36","author":"P\u00e9rez de Isla","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10557-016-6690-1","article-title":"PCSK9: the critical role of familial hypercholesterolemia from discovery to benefit for all","volume":"30","author":"Stein","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/2047487317702040","article-title":"Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia","volume":"24","author":"Rubba","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B34","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/MOL.0000000000000249","article-title":"Cardiac computed tomography imaging in familial hypercholesterolaemia: implications for therapy and clinical trials","volume":"26","author":"Sijbrands","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B35","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B38","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B39","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B40","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1755-5922.12093","article-title":"A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects","volume":"32","author":"Lunven","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B41","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/jcph.866","article-title":"Alternative treatment regimens with the PCSK9 inhibitors alirocumab and evolocumab: a pharmacokinetic and pharmacodynamic modeling approach","volume":"57","author":"Scherer","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B42","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0735-1097(17)33542-8","article-title":"Use of high-intensity statin therapy post-acute coronary syndrome in the ongoing ODYSSEY OUTCOMES trial of alirocumab, a proprotein convertase subtilisin\/kexin type 9 monoclonal antibody, versus placebo: interim baseline data","volume":"69","author":"Goodman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B45","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ijcard.2016.11.046","article-title":"Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: results from three years of treatment","volume":"228","author":"Dufour","year":"2017","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/joim.12614","article-title":"Can LDL cholesterol be too low? Possible risks of extremely low levels","volume":"281","author":"Olsson","year":"2017","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2003.11.002","article-title":"Lipoprotein concentrations in newborns are associated with allelic variations in their mothers","volume":"172","author":"Descamps","year":"2004","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B49","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial","volume-title":"Diabetes Obes Metab","author":"Leiter","year":"2017"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B50","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B52","doi-asserted-by":"crossref","first-page":"132.","DOI":"10.1186\/s12944-016-0302-8","article-title":"Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center","volume":"15","author":"Shah","year":"2016","journal-title":"Lipids Health Dis"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180407055351_ehx549-B54","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/14\/1131\/24554043\/ehx549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T21:39:21Z","timestamp":1719437961000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/14\/1131\/4554775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":54,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2017,10,16]]},"published-print":{"date-parts":[[2018,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx549","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,7]]},"published":{"date-parts":[[2017,10,16]]}}}